Pregabalin in the discontinuation of long-term benzodiazepines' use

Human Psychopharmacology

Volumn 23, Issue 4, 2008, Pages 337-340

  Oulis, Panagiotis ^a   Konstantakopoulos, George ^a   Kouzoupis, Anastasios V ^a   Masdrakis, Vasilios G ^a   Karakatsanis, Nikolaos A ^a   Karapoulios, Evangelos ^a   Kontoangelos, Konstantinos A ^a   Papadimitriou, George N ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Benzodiazepine dependence; Benzodiazepine discontinuation; Pregabalin

Indexed keywords

ALPRAZOLAM; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; BROMAZEPAM; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; CLORAZEPATE; DULOXETINE; ESCITALOPRAM; FLUNITRAZEPAM; FLUOXETINE; FLUVOXAMINE; LORAZEPAM; MIRTAZAPINE; PREGABALIN; QUETIAPINE; SERTRALINE; VENLAFAXINE;

ADULT; AGED; ANXIETY; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DELUSION; DIZZINESS; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; DYSARTHRIA; DYSTHYMIA; FATIGUE; FEMALE; HUMAN; LEG CRAMP; LONG TERM CARE; MAJOR DEPRESSION; MALE; OPEN STUDY; OUTPATIENT; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; TREATMENT DURATION;

ADULT; AGED; ANTI-ANXIETY AGENTS; ANTICONVULSANTS; ANXIETY DISORDERS; BENZODIAZEPINES; COGNITION; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

EID: 47249166163     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.937     Document Type: Article

References (20)

1. American Psychiatric Association. 2000. Diagnostic and Statistical Manual of mental disorders, 4th edition, text revision. American Psychiatric Association: Washington, DC.
2. Ashton H. 2005. The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry 18: 249-255.
3. Denis C, Fatseas M, Lavie E, Auriacombe M. 2006. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. Cochrane Database Syst Rev 3: CD005194.
4. Feltner DE, Crockatt JG, Dubovsky SJ, et al. 2003. A randomized, double-blind, placebo controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 23: 240-249.
5. Folstein MF, Folstein SE, McHugh PR. 1975. 'Mini-Mental State'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
6. Frampton JE, Foster RH. 2006. Pregabalin in the treatment of generalized anxiety disorder. CNS Drugs 20: 685-693.
7. Golombok S, Moodley P, Lader M. 1988. Cognitive impairment in long-term benzodiazepine users. Psychol Med18: 365-374.
8. Hamilton M. 1959. The assessment of anxiety states by rating. Br J Med Psychol 32: 50-55.
9. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
10. Hindmarch I, Trick L, Ridout F. 2005. A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. Psychopharmacology (Berl) 183: 133-143.
11. Kavoussi R. 2006. Pregabalin: From molecule to medicine. Eur Neuropsychopharmacol 16 (Suppl 2): S128-133.
12. Lauria-Horner BA, Pohl RB. 2003. Pregabalin: a new anxiolytic. Expert Opin Investig Drugs 12: 663-672.
13. Montgomery SA. 2006. Pregabalin for the treatment of generalized anxiety disorder. Expert Opin Pharmacother 7: 2139-2154.
14. Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC. 2006. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabaline and venlafaxine. J Clin Psychiatry 67: 771-782.
15. Pande AC, Crockatt JG, Feltner DE, et al. 2003. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 160: 533-540.
16. Pohl RB, Feltner DE, Fieve RR, Pande AC. 2005. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol 25: 151-158.
17. Rickels K, Lucki I, Schweizer E, Garcia-Espana F, Case WG. 1999. Psychomotor performance of long-term benzodiazepine users before, during, and after benzodiazepine discontinuation. J Clin Psychopharmacol 19: 107-113.
18. Shneker BF, McAuley JW. 2005. Pregabalin: a new neuromodulator with broad therapeutic indications. Ann Pharmacother 39: 2029-2037.
19. Stahl SM. 2004. Mechanism of action of alpha2delta ligands: voltage sensitive calcium channel (VSCC) modulators. J Clin Psychiatry 65: 1033-1034.
20. Stewart SA. 2005. The effects of benzodiazepines on cognition. J Clin Psychiatry 66(Suppl. 2): 9-13.